Pfizer Says Lipitor Buyers Can't Bring Antitrust Challenge

Law360, New York (November 19, 2012, 4:36 PM ET) -- Pfizer Inc. sought Friday to end a class action concerning its purportedly anti-competitive settlement resolving patent litigation over Ranbaxy Inc.'s generic challenge to Pfizer's cholesterol drug Lipitor, telling a New Jersey federal court that the drug retailer plaintiffs lack standing to pursue the case.

In a bid for dismissal of claims brought by a group of direct purchaser plaintiffs in the larger multidistrict litigation against Pfizer, Ranbaxy and others, the Lipitor maker took issue with the direct purchasers' right to bring an antitrust suit when they...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required